KRAS and neoplasm: The combination of the FAK-inhibitor defactinib with the dual RAF/MEK inhibitor avutometinib (VS-6766) may overcome this resistance and has shown synergistic antitumor activity in KRAS wild-type LGSOC patient-derived tumor xenografts [85].